Trial reportBMC oral health2026
Clinical feasibility of chairside methylene blue-mediated photodynamic therapy for oral candidiasis.
Trial report in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesOral candidiasis is a common oral mucosal infection, and limitations of conventional antifungal therapy highlight the need for alternative chairside treatment approaches. This study aimed to assess the short-term clinical response, safety, and feasibility of a chairside methylene blue-mediated photodynamic therapy (MB-PDT) protocol for oral candidiasis, and to generate preliminary data to inform the design of future randomized controlled trials.
methodsThis prospective, randomized, open-label, exploratory controlled trial enrolled patients with clinically and mycologically confirmed oral candidiasis between September 2024 and September 2025. Participants were block-randomized into two groups: the MB-PDT group (n = 9), which received chairside MB-PDT using the Periowave
resultsEighteen participants were enrolled, with no significant baseline differences between groups (all P > 0.05). Both groups showed marked improvement in clinical symptoms and mucosal signs. Clinical response rates were 66.7% in the MB-PDT group and 88.9% in the nystatin group (P = 0.576). Mycological clearance rates were 44.4% and 88.9%, respectively (P = 0.131). Comprehensive response rates reached 88.9% in the MB-PDT group and 100.0% in the nystatin group (P = 0.094). No serious adverse events were reported. Two participants withdrew, yielding an overall dropout rate of 11.1%, with good treatment adherence.
conclusionsChairside MB-PDT using a portable Periowave
trial registrationChinese Clinical Trial Registry ID ChiCTR2400088856. Registration Date 28 August 2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.